Cardiol Therapeutics (CRDL) Insider Trading & Ownership C$1.91 -0.15 (-7.28%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock Cardiol Therapeutics (TSE:CRDL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.57%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)C$161.46KNumber OfInsiders Selling(Last 12 Months)0 Get CRDL Insider Trade Alerts Want to know when executives and insiders are buying or selling Cardiol Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CRDL Insider Buying and Selling by Quarter Cardiol Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/26/2024Guillermo TorreSenior OfficerBuy17,240C$1.81C$31,277.7712/19/2024Andrew Warwick HamerSenior OfficerBuy18,900C$1.88C$35,606.6912/17/2024Bernard LimSenior OfficerBuy10,000C$1.95C$19,500.0012/16/2024David ElsleyDirectorBuy40,000C$1.88C$75,072.00 (Data available from 1/1/2013 forward) CRDL Insider Trading Activity - Frequently Asked Questions Who is on Cardiol Therapeutics' Insider Roster? The list of insiders at Cardiol Therapeutics includes Andrew Warwick Hamer, Bernard Lim, David Elsley, and Guillermo Torre. Learn more on insiders at CRDL. What percentage of Cardiol Therapeutics stock is owned by insiders? 4.57% of Cardiol Therapeutics stock is owned by insiders. Learn more on CRDL's insider holdings. Which Cardiol Therapeutics insiders have been buying company stock? The following insiders have purchased CRDL shares in the last 24 months: Andrew Warwick Hamer (C$35,606.69), Bernard Lim (C$19,500.00), David Elsley (C$213,562.00), and Guillermo Torre (C$31,277.77). How much insider buying is happening at Cardiol Therapeutics? Insiders have purchased a total of 136,140 CRDL shares in the last 24 months for a total of C$299,946.47 bought. Cardiol Therapeutics Key ExecutivesMr. David G. Elsley MBAPresident, CEO & DirectorMr. Christopher J. Waddick C.A.C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & DirectorMr. Bernard Lim B.Sc.Chief Operating OfficerDr. Andrew Warwick Hamer M.D. (Age 62)Chief Medical Officer & Head of Research & Development Compensation: $746.56kTrevor BurnsInvestor Relations More Insider Trading Tools from MarketBeat Related Companies FRX Insider Transactions APM Insider Transactions GXE Insider Transactions MDNA Insider Transactions CGC Insider Transactions RGC Insider Transactions ASND Insider Transactions NBY Insider Transactions GRI Insider Transactions PBM Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (TSE:CRDL) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
